Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 132 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Benralizumab for treating hypereosinophilic syndrome	Benralizumab (Fasenra; MEDI563)	Hypereosinophilic syndrome (HES)	Immunology	2023	View \| Download
BI 907828 for previously untreated advanced dedifferentiated liposarcoma	BI 907828	Advanced dedifferentiated liposarcoma	Sarcoma	2023	View \| Download
Bifikafusp alfa-onfekafusp alfa neoadjuvant therapy for treating resectable stage IIIB and IIIC melanoma	Daromun	Melanoma	Skin Cancer	2023	View \| Download
Botaretigene sparoparvovec for treating X-linked retinitis pigmentosa	Botaretigene sparoparvovec	Retinitis pigmentosa	Ophthalmology	2023	View \| Download
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma	Brentuximab vedotin (Adcetris; SGN-35) , Dacarbazine (dacarbazine citrate) , Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) , Vinblastine (vinblastine sulfate)	Hodgkin lymphoma	Haematological Cancer and Lymphomas	2023	View \| Download
Cabotegravir (long-acting injection) for prevention of HIV-1 infection	Cabotegravir (GSK1265744)	HIV-1 infection	Infectious Disease	2023	View \| Download
Cabozantinib with atezolizumab for treating metastatic castration-resistant prostate cancer after one novel hormonal therapy	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Prostate cancer	Haematological Cancer and Lymphomas , Oncology	2023	View \| Download
Cabozantinib with nivolumab and ipilimumab for previously untreated advanced or metastatic renal cell carcinoma	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2023	View \| Download
Canagliflozin for type 2 diabetes mellitus in children and adolescents	Canagliflozin (Invokana; canagliflozin hemihydrate)	Type 2 diabetes	Endocrine, nutritional and metabolic disorders	2023	View \| Download
Capivasertib with fulvestrant for HR+/HER2- locally advanced or metastatic breast cancer	Capivasertib , Fulvestrant (Faslodex)	Breast cancer	Breast Cancer	2023	View \| Download